BridgeBio Pharma, Inc.
BBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. Valued at $15.94B, BBIO is a large-cap name in its sector. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Market Cap
$15.94B
Beta
0.95
P/E (TTM)
—
P/E (Fwd)
137.90
EPS (TTM)
$-3.74
EPS (Fwd)
$0.59
ROE
—
ROA
-28.0%
Cash
$940.2M
Total Debt
$2.49B
Free CF
-$317.9M
52W Change
75.0%
Annual Financials
Cash vs Debt
BridgeBio Pharma, Inc. carries $2.49B in total debt against $940.2M in cash reserves — debt is roughly 2.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$317.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $77.6M (2022) to $502.1M (2025), reflecting a 547% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing BBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.